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Adenovirus is one of the most commonly used vectors for gene therapy and it 
is the first approved virus-derived drug for treatment of cancer.  As an oncolytic 
agent, it can induce lysis of infected cells, but it can also engage the immune 
system, promoting activation and maturation of antigen-presenting cells 
(APCs). In essence, oncolysis combined with the associated 
immunostimulatory actions result in a “personalized in situ vaccine” for each 
patient.  In order to take full advantage of these features, we should try to 
understand how adenovirus interacts with the immune system, what are the 
receptors involved in triggering subsequent signals and which kind of 
responses they elicit. Tackling these questions will give us further insight in how 
to manipulate adenovirus-mediated immune responses for enhancement of 
anti-tumor efficacy.   
In this review, we first highlight how oncolytic adenovirus interacts with the 
innate immune system and its receptors such as Toll-like receptors, nucleotide-
binding and oligomerization domain (NOD)-like receptors and other immune 
sensors.  Then we describe the effect of these interactions on the adaptive 
immune system and its cells, especially B and T lymphocytes. Finally, we 
summarize the most significant preclinical and clinical results in the field of gene 
therapy where researchers have engineered adenovirus to manipulate the host 
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Immune system and adenovirus: toxicity or efficacy? 
 
Innate immune responses are triggered when pattern-recognition receptors 
(PRRs) recognize specific conserved molecular patterns on pathogens. 
Several classes of PRRs, including Toll-like receptors, NOD-like receptors and 
various cytoplasmic receptors, recognize distinct microbial components and 
directly activate immune cells. Exposure of immune cells to the ligands of these 
receptors activates intracellular signaling cascades that rapidly induce the 
expression of a variety of both overlapping and unique genes involved in the 
ensuing immune responses. Activation of PRRs results in the production of 
large amounts of type I interferons and several other proinflammatory cytokines 
1-2. These responses are important in controlling pathogen replication and they 
also provide a critical initiation signal which modulates and controls the 
adaptive immune response 3-4. 
Adenovirus is the most commonly used gene therapy vector. It is mostly used 
in the context of genetic diseases or cancer, or for vaccination 5-18. 
Adenoviruses interact with multiple PRRs (Figure 1) eliciting a robust cytokines 
response 19-20. With regard to conventional gene delivery, virus-induced 
inflammation can lead to premature vector elimination, and at the doses 
required for sufficient liver transduction adenovirus can be toxic 19-20.  We and 
others have hypothesized that we can harness the natural propensity of 
adenovirus to activate the innate and adaptive arms of the immune system 
against the tumor.  While oncolysis would provide initial cell killing with an 
associated release of a variety of tumor associated antigens (TAAs), 
immunological recognition of the virus would provide the required “danger 
signal” to mature and stimulate antigen presenting cells (APCs, eg. dendritic 
cells, DCs). Along this line, investigators have recently demonstrated that 
oncolytic adenoviruses have the capability to stimulate a specific antitumor 
immune response 21-23.   
We hypothesized that oncolysis driven by the viruses plays a double role: 1) 
lysis of tumor cells resulting in a source of tumor-associated antigens (TAAs) 
2) “danger signals” to the immune system to enhance cross-priming of antigen 
presenting cells (APCs) rather than cross-tolerization (Figure 2).  Moreover, 
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oncolytic adenovirus can be armed to specifically stimulate pathways of the 
immune system  for an enhanced antitumor response (Figure 3). Importantly, 
cross-presentation and epitope spreading has been demonstrated, suggesting 
that cellular anti-viral responses can result in immunity against TAA as well 24. 
In particular, memory responses against TAA may be important for long term 
survival of treated patients 25-27. Even though the main goal of arming is typically 
enhancing efficacy, also safety could be increased, if lower doses can be used, 
or if the arming device results in less systemic dissemination of the virus.  
Thus, for optimal modulation of the immune system against the tumor we need 
to understand what are the key receptors the adenovirus interacts with. 
 
 
Adenovirus interaction with the innate immune system 
 
Adenovirus and TLRs 
The innate immune system recognizes infections through PRRs that detect 
conserved microbial components called pathogen-associated molecular 
patterns (PAMPs). PAMPs represent molecules vital for microbial survival such 
as flagellin, nucleic acid structures unique to bacteria and viruses (CpG DNA, 
dsRNA), and bacterial cell-wall components such as lipopolysaccharide (LPS), 
lipoteichoic acid, and peptidoglycan 28. More than a decade ago, the protein 
Toll was identified as a key regulator of innate immune signaling in Drosophila 
melanogaster 29. Since then, mammalian Toll-like receptors (TLRs) have been 
recognized for their ability to sense a wide array of microbial and self-ligands at 
the cell surface and within endosomes 30. TLRs comprise of 11 different 
receptors that recognize motifs found on a wide range of pathogens, and 
activation of TLRs results in the production of large amounts of type I interferons 
and several pro-inflammatory cytokines. These cytokine responses are 
important in controlling pathogen replication and they provide an initiation signal 
for the adaptive immune response. 
Adenovirus capsids activate the innate immune system through mechanisms 
that do not involve viral replication or gene expression 19, 31-36.  For example, 
following exposure to UV-inactivated adenovirus, human peripheral blood 
mononuclear cells (PBMCs) rapidly produce many cytokines, including IL-6, IL-
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1β, granulocyte monocyte colony stimulating factor (GMCSF), IL-8, and TNF-α 
37.  A similar cytokine profile is also found in the serum of mice and non-human 
primates following intravenous administration of adenovirus 19, 34, 36, 38. Also 
dendritic cells produce large amounts of cytokines and type I interferons 
immediately after infection with adenovirus 38-40. 
Recent literature has started to link these phenomena with specific stimulation 
of TLRs (Figure 1).  We showed that adenovirus DNA triggers innate responses 
in part via TLR9 36, one of the PRRs located in the endosome and responsible 
for detecting double-stranded DNA.  It was also observed that mice lacking the 
Myeloid differentiation primary response gene 88 (MyD88), a universal adapter 
protein used by all TLRs (except TLR3) to activate the transcription factor NF-
κB and trigger the immune response, showed significantly reduced cytokine 
secretion when challenged with high dose of adenovirus, indicating that TLR9 
is involved in adenovirus recognition 41.  Later, it was shown that TLR9 and 
TLR2 are both required to trigger the MAP-kinase dependent inflammatory 
response characteristic of adenoviral vector administration 42.  This data was 
confirmed in 2010 by Suzuki and colleagues who showed that TLR2 and TLR9 
are responsible for induction of cytokines and gene silencing in mice following 
adenoviral vector administration 43.  Interestingly, they showed that when LacZ-
expressing adenoviral vectors were administered intravenously in MyD88 
knock-out mice (lacking almost all TLRs-mediated responses) not only was 
cytokine secretion significantly lower but also transgene expression was 
significantly prolonged due to absence of a normal immune response 43. These 
results highlighted the importance of the TLRs in initiatiation of the innate 




Adenovirus and cytosolic sensors 
Nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) 
comprise a large family of intracellular PRRs that are characterized by the 
presence of a conserved NOD 45. Together with retinoid acid-inducible gene I 
(RIG-I)-like receptors (RLRs), NODs detect microbial components in the cytosol 
46-47. NLRs containing NOD1 and NOD2 sense the dipeptide γ-D-glutamyl-
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meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP), 
respectively 48. Both are breakdown products of bacterial peptidoglycan. NOD1 
is ubiquitously expressed and occurs in most NLRs, while NOD2 are restricted 
to monocytes, macrophages, dendritic cells and intestinal Paneth cells 49. 
Very little is known to date about the correlation between adenovirus and 
NOD-like receptors recognition. Recently, Suzuki and colleagues showed 
reduced proinflammatory cytokine secretion and significantly higher transgene 
expression when NOD2 KO mice were challenged with non-replicating 
adenoviral vectors. Moreover, experiments in NOD2/MyD88 double KO mice 
showed further reduced innate responses to adenoviral vectors compared to 
responses in singly deleted mice, indicating that NOD2 signaling contributes to 
the innate responses independently of MyD88 50. 
The NALP proteins are cytoplasmic NLRs 51. The best characterized is NALP3 
(also called cryopyrin, NLRP3), which senses exogenous and host ligands such 
as bacterial peptidoglycan, ATP or uric acid 52. NALP3 recruits, via the adaptor 
protein ASC, the inflammatory caspase-1 into a molecular complex termed the 
NALP-inflammasome 52. Once activated, caspase-1 processes pro-IL-1b and 
pro-IL-18 to their active and secreted forms. Other NLRs that are known to form 
IL-1b-processing inflammasomes include NALP1 and IPAF, the latter of which 
directly activates caspase-1 in response to bacterial flagellin 53. 
In an elegant study, Petrilli and colleagues showed that internalized 
adenovirus DNA triggers an innate immune response dependent on the 
activation of the NALP-inflammasome complex (NALP3 and ASC) 54. Already 
earlier, Nociari and colleagues demonstrated that TLR-independent adenovirus 
DNA recognition led to IRF3 activation and type I IFN and proinflammatory 
cytokine expression 55. Also, cytosolic DNA recognized by AIM2 was shown to 
induce IL-1b secretion through a caspase-1-dependent inflammasome 
pathway 56. 
Among other cytosolic sensors, retinoic acid-induced gene I (RIG-I) plays an 
important role in promoting IFN production in response to pathogens.  RIG-I-
like receptors (RLRs), such as RIG-I, MDA5 and LGP2, feature a helicase 
domain that senses RNA strands. These proteins can distinguish foreign (i.e. 
viral) RNAs from self-RNAs that feature a 5´ modification. The N-terminal 
domain contains a caspase activation and recruitment domains (CARD) able to 
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signal through mitochondrial antiviral signaling protiens (MAVS) 57. 
Interestingly, in addition to viral RNA, also DNA is sensed through RLRs. Chiu 
and colleagues demonstrated that transfection of human cells with different 
DNA forms, including poly(dA-dT), PCR fragments or DNA oligos activated 
IRF3. This resulted in the production of IFN- β. The effect was inhibited when 
RIG-I or MAVS were silenced into the cell line, suggesting an important role of 




Adenovirus and Complement 
Together with antibodies, complement plays a role in vector opsonization and 
clearance. Adenovirus has been shown to activate complement via antibodies 
in individuals having pre-existing immunity 59. Also, direct binding to C3-derived 
fragments has been reported 59. Such interactions can probably contribute to 
inflammatory responses associated with virotherapy 60. In fact, steps have been 
taken to mask complement-mediated recognition of adenovirus particles with 
the goal of increasing vector efficacy 60. Thrombocytopenia is caused by 
interactions between adenoviral particles and the coagulation system, resulting 
in platelet activation, binding to endothelial cell surfaces, and formation of 
platelet-leukocyte aggregates 61. Finally, Ad vectors directly and indirectly 
activate endothelial cells primarily via recognition of virus capsid 31. 
 
 
Adenovirus modification for enhanced innate immunity  
Considering how articulated and complex innate sensing of adenovirus is, and 
considering how various cellular sensors can influence and shape the long-
lasting adaptive response, we believe that the innate arm of the immune system 
can be utilized in the treatment of cancer in an approach that could be defined 
as ImmunoVirotherapy. It is presently being discovered that we can exploit 
oncolytic viruses not only for their killing capacity but also for their ability to 
activate receptors of the innate immune system, translating into specific anti-
tumor responses.  However, in spite of their robust ability to stimulate innate 
sensors, human data suggests that oncolytic adenoviruses per se are not 
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usually able to elicit immune responses capable of fully eradicating metastatic 
tumors, possibly due the highly immune suppressive nature of advanced 
cancers 
Hence, researchers have now entered a new era where they are genetically 
manipulating adenoviruses to enhance activation of some specific innate 
receptors. In this respect, an interesting approach is generation of an oncolytic 
adenovirus expressing the pan-TLR adaptor protein MyD88. Tantalizingly, 
intratumoral injection of Ad-MyD88 into established tumor masses enhanced 
adaptive immune responses and inhibited local tumor immunosuppression, 
resulting in significantly inhibited local and systemic growth of multiple tumor 
types. Further, Ad-MyD88 infection of primary human dendritic cells, tumor-
associated fibroblasts, and colorectal carcinoma cells elicited significant Th1-
type cytokine responses, resulting in enhanced tumor cell lysis and expansion 
of human tumor antigen–specific T cells 62. 
 
 
Adenovirus interaction with the adaptive arm of the immune system 
 
Adenovirus and B cells 
As consequence of the activation of the innate recognition receptors, a rapid 
increase in several cytokines, particularly IL-6, IFN-α/β, RANTES, IL-12 (p40), 
IL-5, G-CSF and GM-CSF is observed 38. Furthermore, a complex set of 
interactions between the innate and the adaptive immune system results in 
activation of CD4+ and CD8+ T cells, and B cells 38. Type I IFN signaling is 
important for T help-dependent antibody formation by B cells. IFNs also induce 
DC maturation by up-regulating co-stimulatory molecules such as CD80, CD86, 
and CD40. Neutralizing antibodies against IFN-α and IFN-β have been found 
to be effective in blocking both innate as well as adaptive immune responses 
to viral vectors 63.  
Understanding the humoral immune response to adenovirus is of importance 
for gene delivery for at least two reasons: 1) presence and prevalence of 
neutralizing antibodies to adenovirus (NAB) might hinder the efficiency of the 
transduction while 2) the presence of NAB might influence the outcome of the 
therapy at post-tranductions steps.Epidemiological studies on NAB in different 
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populations have shown that mostly people in the world already carry some 
levels of antibodies in their serum, although some geographical variation does 
occur 64. It however, needs to be emphasized that the specificity and 
immunogenicity of adenovirus type 5 NAB elicited by natural infection or by 
immunization with an adenoviral vector is quantitative and qualitative different 
65. In this study, 1904 participants were enrolled in a cross-sectional serological 
survey at seven sites in Africa, Brazil, and Thailand to assess neutralizing 
antibodies (NAB) for adenovirus types Ad5, Ad6, Ad26 and Ad36. Clinical trial 
samples were used to assess NAB titers from the US and Europe. The 
proportions of participants that were negative were 14.8% (Ad5), 31.5% (Ad6); 
41.2% (Ad26) and 53.6% (Ad36).  The study was conducted to correlate high 
Ad5 titers and the inefficiency of Ad5-based vaccine for HIV.   
It would be very interesting to conduct a similar study correlating the efficacy 
of oncolytic adenovirus treatment in terms of overall survival (OS) or 
progression free survival (PFS) with the pre-existing NAB presence.  Thus far, 
we have not seen correlation between oncolytic virus treated patients and 
efficacy 66-67.  Interestingly, we saw lower NAB levels than have been reported 
in previous studies. One month after the treatment high NABs against Ad5, an 
RGD-4C modified Ad5 capsid, or a Ad5/3 chimeric capsid were seen in only < 
20, < 50 and < 20 % of patients respectively. In other words, low or negative 
titers were present in 80, 50 and 80% of patients. Differences between different 
reports could be due to geographical factors, the patients studied (cancer 
versus healthy), methodological issues (sensitivity and specificity of the test 
used) or a combination thereof.  
 
 
Adenovirus and T cells 
CD4+ and CD8+ T cells cross-reactive against different adenovirus serotypes 
have been found among human peripheral blood mononuclear cells (PBMCs) 
68-69. Adenovirus-specific CD4+ T cells often recognize epitopes conserved 
among different serotypes, with the majority of people developing a long-lived 
memory response.  
Further, adenovirus-specific secretion of IFN-γ from PBMCs has been 
reported to occur within 12 hours of exposure, suggesting prior activation of 
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adenovirus-specific CD8+ cells. Transduction of APCs by adenoviruses 
contributes to CD8+ responses, which can be directed against both viral gene 
and transgene products and are dependent on CD4+ help 70. 
It has in fact been demonstrated that already adenovirus per se, given its 
ability to interact with a variety of receptors of the innate immune system, is 
able to trigger a T cell immune response in context of cancer therapy.  Tuve 
and colleagues, using a model of syngeneic mammary-cancer have shown 
that intratumoral injection of replication-deficient, transgene-devoid 
adenovirus induces responses at two different anatomical sites: the tumor-
draining lymph nodes and the tumor microenvironment. The lymph nodes 
supported the generation of both neu- and virus-specific T effector cells, while 
inside the tumor microenvironment only adenovirus-specific T cells expanded. 
Importantly, Ad-specific T cells were anti-tumor-reactive despite the presence 
of active regulatory T cell-mediated immune tolerance inside tumors. 
Moreover,  efficacy was increased by pre-immunization regardless of NAB 71.   
The structure of the adenovirus features a plethora of immunogenic signals 
that are sensed by the innate immunity and translated into adaptive 
responses. For this reason, adenoviral particles can act as adjuvant becoming 
a powerful cancer vaccine platform. We further developed this concept and 
demonstrated that, even in absence of oncolysis, the physical combination of 
virions and MHC-I epitopes results in antigen-specific responses. Hence, 
peptide-coated conditionally replicating adenoviruses (PeptiCRAds) are able 
to stimulate dendritic cells and activate antigen specific T-cells resulting in 
reduced growth of treated and non-treated melanomas. We were also able to 
confirm this results in humanized mice, which represents the most advanced 
model available to study the synergy between oncolytic adenoviruses and the 
immune system 72. Our results suggest that oncolysis is not necessary for anti-
tumor activity, however we believe that it provides important additional pro-
inflammatory stimuli to the immune system as proved by our studies in 
humanized mice. 
Syrian hamsters provide key advantages when studying oncolysis due to the 
ability of human adenoviruses to replicate into hamster tumor cells. By using 
this model, Wang and colleagues were able to show that the efficacy of 
oncolytic adenoviruses is largely mediated by T-lymphocytes. They 
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demonstrated that viral replication inside tumors is enhanced by depletion of 
T-cells, however, this abrogates the efficacy of virus injections. Hence, the 
presence of T-lymphocytes is necessary for the anti-tumor efficacy of oncolytic 
adenoviruses in this model 73. Siurala and colleagues also investigated the 
synergy between oncolytic adenoviruses and lymphocytes. They observed 
that the combination of oncolytic Ad5-D24 with adoptive transfer of tumor 
infiltrating lymphocytes (TILs) reduced the growth of HapT1 pancreatic cancer 
in syngeneic Syrian hamsters 74.  
We have treated more than  200 cancer patients with armed and un-armed 
oncolytic adenoviruses, and have observed activation of CD8+ T cells against 
both virus and tumor epitopes 75-80. In addition, we have recently described 
different factors that might predict the response of patients to oncolytic 
virotherapy. We found that administration route, absence of liver metastasis 
or low neutrophil-to-lymphocytes ratio were significantly correlated with a 
better prognosis 81. Thus, our data suggests that adenovirus can be a useful 




Oncolytic Adenovirus Armed with Immunomodulatory Transgenes 
 
In spite of emerging data showing induction of anti-tumor specific immune 
response elicited by oncolytic adenoviruses per se, a strong anti-tumor immune 
response capable of complete rejection and eradication of advanced tumors is 
rarely seen.  Tumors initiate from normal tissues and thus most TAA are  
resemble self-antigens which results in lower immunogenicity in comparison to 
heterologous epitopes such as PAMP 82-83. Further, since tumors typically grow 
over a decade of more in the presence of an intact immune system, a 
tremendous amount of immunoediting (ablation of immunogenic clones) has 
usually occurred 84-85. Also, as mutations accumulate, and tumor cells resemble 
normal cell less and less, an increasing amount of immune suppression is 
required 86-88.  Thus, the biggest challenge for cancer immunotherapy in general 
and immunovirotherapy in particular could be manipulation of the tumor 
microenvironment in favor of immune responses rather than tolerance.  In this 
12 
regard, encouraging results have been achieved using oncolytic adenoviruses 
armed with transgenes for modulation of both the innate and adaptive immune 
systems (Table 1). Moreover, viruses encoding monoclonal antibodies, such as 
anti-HER2 Trastuzumab, have been evaluated. The main advantages of this 
approach are intra-tumor production and decreased side-effects caused by the 




Cytokines are used by the immune system for cross-talk between different cell 
types and are thus easily harnessed as arming devices. One widely used 
cytokine in this respect is interleukin 12 (IL-12) 90-105.  This cytokine is an 
interleukin naturally produced by antigen presenting cells (APCs) in response 
to antigenic stimulation.  As a consequence of interaction with its receptors (IL-
12R-β1 and IL-12R-β2) L-12 activates natural killer cells (NK) and T 
lymphocytes (T cells) enhancing their cytotoxic activity.  T and NK cells produce 
IFN- in response of IL-12 activation.  Oncolytic adenoviruses expressing IL-12 
have demonstrated to enhance T cell and NK activation several tumor model 
in mice and human 90-91, 93-109.   
One interesting report focused on Syrian hamsters, which is one of the few 
models considered semi-permissive for human adenovirus 110. An oncolytic 
adenovirus expressing IL-12 driven by the viral E3 promoter was capable of 
curing syngeneic pancreatic tumor in conjunction with an anti-tumor immune 
response measurable by T cell proliferation111. This work also suggested partial 
cross-reactivity between mouse and Syrian hamster cytokines since they used 
murine Il-12.  In another study, Gabaglia et al. reported that the treatment of 
human PC3 prostate xenograft or TRAMP-C1 tumors with the combination 
Ad5IL-12 and mifepristone produced significantly better therapeutic efficacy in 
comparison to controls 112.  . In particular, they found that combination therapy 
increased the capacity of tumor sentinel lymph node lymphocytes to produce 
granzyme B in response to tumor cells. Finally, combination therapy groups 
had fewer CD4+/FoxP3+ T regulatory cells in local nodes.   
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A clinical trial using an IL-12 expressing adenovirus reported twenty-one 
patients (nine with primary liver, five with colorectal, and seven with pancreatic 
cancers) treated with  a total of 44 injections. Ad.IL-12 was well tolerated, and 
dose-limiting toxicity was not reached, nor were adverse events cumulative. 
Frequent but transient adverse reactions, including fever, malaise, sweating, 
and lymphopenia, seemed to be related to vector injection rather than to 
transgene expression.. In four of 10 assessable patients, a significant increase 
in tumor infiltration by effector immune cells was apparent. A partial objective 
remission of an injected tumor mass was observed in a patient with 
hepatocellular carcinoma. Stable disease was observed in 29% of patients, 
mainly those with primary liver cancer 113.  
Granulocyte-macrophage colony-stimulating factor (GMCSF) is among the 
most potent inducers of anti-tumor immunity 114.  It acts through several 
mechanisms, including direct recruitment of natural killers (NK) and APCs such 
as dendritic cells (DC) 115-116. GMCSF can also specifically activate DCs at the 
tumor site to increase their expression of co-stimulatory molecules to enhance 
cross-priming and T cell activation rather than cross-tolerance.  We showed  
that Syrian hamsters challenged with a syngeneic pancreatic tumor developed, 
after treatment with the GMCSF-expressing virus, a specific anti-tumor 
response capable of protecting animals from successive challenge by  the 
same tumor but not by different tumors 117. Since a virus armed with human 
GMSCF was more immunogenic than an unarmed virus, these results also 
suggested that human GMCSF is active in Syrian hamsters. Importantly, 
preclinical results were followed up by treatment of humans, resulting in data 
suggesting induction of  a tumor-specific immune response also cancer 
patients, as measured by ELISPOT and pentamer staining 117-118. A recent 
study evaluated the efficacy of an oncolytic (D24 mutation) and chimeric Ad5/3 
virus expressing GMCSF in combination with standard-care chemotherapy 
against mesothelioma119. Unfortunately, evaluating the immunological effects 
of the combination was not possible since the study featured a immune deficient 
xenograft murine model. Nevertheless, the researchers found that the oncolytic 
adenovirus could induce immunogenic cell death in vitro suggesting that the 
oncolytic activity might re-shape the tumor microenvironment. 
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IL-23 is a cytokine similar to IL-12 and in fact they share their p40 subunit. 
However, IL-23 has a preference for memory CD4+ T cell 120-121.  Recently, IL-
23 together with IL-6 and TGF-b1 have been implicated in the mechanism that 
stimulates naive CD4+ T cells to differentiate into Th17 cells, which are distinct 
from classical Th1 and Th2 cells 122. Th17 cells produce IL-17, a 
proinflammatory cytokine that enhances T cell priming and stimulates the 
production of proinflammatory molecules 123.  Reay and colleagues showed that 
three intratumoral injections of adenovirus expressing IL-23 significantly 
increased animal survival and resulted in complete rejection of 40% of tumors, 
with subsequent generation of protective immunity and tumor-specific cytotoxic 
T lymphocytes. In addition, they showed that the antitumor activity of IL-23 was 
independent of IL-17, perforin and Fas-ligand, but dependent on interferon-, 
CD4 and CD8 T cells 124.  
 
 
Interferon -expressing adenovirus 
 
Interferons (IFNs) are small protein made and released by the host cell to 
counteract the effect of pathogens, in particular viruses.  IFNs are roughly 
divided into two subclasses: type I (alpha,  and beta, ) 125 and type II (also 
called late IFNs) such as INF-126. There is extensive data showing that IFNs 
are not only important in protection of normal tissues against pathogens, but 
they have also been shown to have anti-tumor activity directly on tumor cells 
and through  activation of the immune system 127-128. 
Although generating an adenovirus that expresses IFNs might seem 
counterintuitive due to the anti-viral activity of the latter, rationale is present due 
to near-universal deficiency of tumors to IFN signaling 129-130. Thus, arming with 
IFN can increase the therapeutic window between actions on normal and tumor 
tissues and has been successfully used in several cancer type 131.  
Interestingly, Santodonato and colleagues showed also anti-tumor activity in 
IFN-resistant tumors in mice when treated with an IFN-alpha expressing 
adenovirus 132. Interestingly, it has been also reported efficacy and anti-tumor 
immunity with IFN- expressing adenovirus even in very difficult tumors as 
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pancreatic cancer 133.  Similar results were also obtained in Syrian hamsters133.  
More recently it has been proposed that anti-tumor immunity can depend on 
the route of administration 134 and that IFN- resistant tumors can be killed 
throughtumor immunity, oncolysis and autophagy 135. The efficacy of an 
adenovirus encoding for INF-has been evaluated in a phase II clinical trial in 
patients with cutaneous B-cell lymphomas (CBCL). Complete or partial 
responses were observed in 85% of patients and one patient experienced 
stable disease. In addition, all skin biopses showed a decrease of the lymphoid 
infiltrate in the lesions 136. The same IFN-armed adenovirus (TG1042) was 
tested in combination with adoptive T-cell transfer therapy in 13 patients with 
unresectable stage III or stage IV melanoma. Three patients presented a 
complete regression, two patients experienced partial response and one patient 
presented a stable disease; the median overall survival was 21.1 months 137. 
An alternative but equally attractive approach is represented by expression of 
IFN-beta.  Already in 2001 Odaka et al. showed that a non-replicating 
adenovirus expressing murine IFN- was able to eradicate intraperitoneal and 
distant syngeneic mesothelioma tumors by inducing anti-tumor immunity, as 
shown by reactive CD8+ T cells and loss of activity in group of mice depleted 
of CD8+ T cells 138.   139. An interesting comparison between human and mouse 
IFN-beta expressing adenovirus in different tumor models was reported by Qin 
et al. 140.  Although many actions of IFN are through the adaptive arm of the 
immune system, an interesting role has also been proposed for macrophages 
141. A promising proof-of-concept study was performed by Park et al. who 
reported that a combination of oncolytic adenovirus Ad5D24RGD and a non-
replicating adenovirus coding for IFN-b resulted in a high local concentration of 
IFN-beta. Importantly, local release of tumor antigens by oncolysis induced a 
strong antitumor immune response142. These preclinical reports have been 
followed up in several clinical trials in human patients 143-146. 
 
 
Surface Protein expressing adenoviruses 
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The basic theories of immunology predict that when an antigen-presenting cell 
(APC) such as a dendritic cell (DC) is presenting an antigen to a T cell, it has 
the ability to decide whether or not there will be immune response or anergy of 
that specific cell. Normally, peptides derived from endogenously expressed 
proteins are presented by APC in the context of MHC class I (MHC I) to CD8+ 
T cells, whereas peptides obtained from exogenously derived proteins are 
normally loaded onto MHC class II (MHC II) for presentation to CD4+ T cells. 
However, exogenous antigens can be also loaded onto MHC I for ‘‘cross-
presentation’’ to CD8+ T cells 147.  In tumor-draining lymph nodes both cross-
priming and cross-tolerization have been reported, tumor antigen–specific T-
cell proliferation has been detected, but the numbers of T cells proliferating are 
typically too low, and therefore the overall effect of CD8+ T-cell activation does 
not always result in inhibition of tumor outgrowth 148. 
To enhance T cell activation it has been proposed to over-express co-
stimulatory factors that act directly on T cells.  CD154, better known as CD40L, 
is one of the most used.  Normally it binds to CD40 on APC, which leads to 
many effects depending on the target cell type. In general, CD40L plays the 
role of a co-stimulatory molecule and induces activation in APC in association 
with T cell receptor stimulation by MHC molecules on the APC.  In our 
laboratory we have generated an oncolytic virus expressing CD40L.  This 
approach has shown remarkable efficacy in animal models as well as good 
safety and evidence of activity in human patients 149-150.    
A similar approach is the expression of CD80, which is also called B7-1.  This 
is a membrane protein especially expressed by B cells, monocyte and APCs, 
that provides a powerful co-stimulatory factor for T cell activation and survival.  
B7-1 is the ligand for CD28 and for CTLA-4.  Along this line it has been shown 
that an adenovirus expressing IL-7/B7.1 induces rejection of transplanted 
tumors in mouse model151.  The authors conclude suggesting that cancer 
vaccines can be effective against “minimal residual disease” but additional 
experimental procedures must be found against established non-transplanted 
tumors.  A similar approach has been also described in the same year by a 
different group that generated an adenovirus expressing IL-12/B7.1152.  They 
showed that the efficacy of this virus was dependent on NK cells as well as T 
cells, and loss of efficacy was in fact observed in NK- or T cell- depleted 
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animals.  Moreover they showed that the efficacy of this virus was further 
enhanced by combination with radiotherapy 152.  More recently, a virus 
expressing a newly discovered member of B7 family, B7-H3, was reported.  The 
mouse protein shares about 88% amino acid identity with the human. Unlike 
B7-H1 and B7-H2, its mRNA is broadly expressed in lymphoid and non-
lymphoid organs153. B7-H3 has been shown to costimulate the proliferation of 
CD4+ and CD8+ T-cells and to stimulate interferon-γ (IFN-γ) production and 
cytolytic T-cell activity154. A study also demonstrates that adenoviral B7-H3 
transfer is able to induce a specific cellular antitumor immune response leading 




For the past decade, many  gene therapy approaches have attempted to fight, 
avoid or suppress  the immune system in order to retain efficacy similar to seen 
in nude mouse models. However, many investigators in the cancer field have 
realized that an alternative approach could be to ally with it to stimulate and 
shape the immune response towards the tumor.  In the context of cancer 
therapy, adenovirus is an attractive agent due to its  extraordinary ability to 
interact with different pathways of the innate and adaptive immune system. 
Not only is there scientific interest in elucidating how different wild type viruses 
or their therapeutically-aimed derivatives induce different types of immune 
responses, but this information also has significant applied potential. For 
example, it was recently proposed that in contrast to the commonly used 
adenovirus serotypes 5 or 35, vectors based on serotype 28 suppressed 
proinflammatory cytokine secretion while eliciting strong type I interferon 
secretion, ultimately resulting in greater vaccination efficacy 156. Thus, the 
quality rather than the quantity of the immune response could be an important 
determinant of the overall outcome. The authors speculated that the differential 
TLR sensing and signaling by this virus in comparison with the other serotypes 
in the study resulted in optimal cytokine secretion by DCs and subsequently 
superior activation of the adaptive immune response. In another study, despite 
higher uptake and subsequent maturation of DCs, Ad35 was shown to interfere 
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with NFkB activation and result in reduced activation of CD4+ T cells compared 
to Ad5 157. 
While many immunostimulatory approached have been proposed to have 
desirable qualities for tumor immunotherapy, they may be insufficient on their 
own to achieve full and long-lasting tumor control. In particular, emerging data 
suggests that induction of immunity may not be enough, due to the immune 
suppressivity of the tumor environment. Thus, selective combinations of 
immune stimulation with reduction of suppression are being explored. As an 
example, GM-CSF synergized with B7-1 to provide superior tumor control in a 
mouse model of metastasizing melanoma 158. It is still relatively unclear, 
however, how each agent shapes the immune response and how best to 
combine different modalities for  maximal net anti-tumor effect. We foresee this 
line of research to gather increasing interest in the coming years. However, the 
biggest problem in the field relates to animal models. Regulation and function 
or different pathways tend to vary between animals and few signaling 
molecules cross species. Thus, models tend to be poorly predictive. Although 
this is especially problematic in the oncolytic adenovirus field since human 
viruses do not replicate productively in most species, the Syrian Hamster may 
be of some utility, if immunological reagents can be developed for it. 
Nevertheless, given the complexity of immunological pathways, human 
translation is critically important but unfortunately difficult and expensive.  
Despite the above-mentioned concerns regards pre-clinical models, the 
pharmaceutical industry has invested many resources into the study of 
advanced virus-based immunotherapies, as demonstrated by the acquisition 
of OncovexGMCSF (now T-vec) 159 by Amgen Inc. for 1 billion US dollars 
(http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1519312). 
Amgen completed a randomized phase 3 study (OPTIM) in patients with 
stage IIIb, IIIc or IV melanoma with unresctable but accessible lesions. 
Interestingly, the trial compared also pre-treated or treatment-näive patients. 
Patients receiving T-vec experienced increased durable responses compared 
with the control group (patients receiving GM-CSF alone) 160. Patients with 
lower stages of melanoma had increased both durable response rate (DRR) 
and objective response rate. In addition, treatment-näive patients had 
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increased DRR compared to patients receiving T-vec as second-line therapy 
161. The success of T-vec in melanoma encouraged researchers and clinicians 
to study other types of cancer and new trials have been designed to test the 
combination of this oncolytic virus with immune checkpoint inhibitors such as 
ipilimumab (anti-CTLA4; NCT01740297) or pembrolizumab ( anti-PD1; 
NCT02263508). The positive results in clinical studies finally led to the 
approval by FDA of T-vec for the treatment of advanced melanoma on 27 
October 2015 162. These studies have important consequence also for the 
research based on adenoviral vectors. In fact, the development of optimized 
treatment schedule, dosages and immunological analysis are common 
challenges. We believe that the results and the re-newed enthusiasm towards 
this field will be at the basis of future clinical trials featuring oncolytic 
adenoviruses. 
Overall, it is remarkable how rapidly rationally designed oncolytic viruses have 
entered clinical use, perhaps facilitated by a century of work with non-modified 
lytic viruses 163. The first oncolytic adenovirus product was approved in China 
after a mere decade after the first preclinical report 164, and has subsequently 
acquired safety and efficacy data in more than 5000 patients . In the West, the 
efficacy of an oncolytic adenovirus mediated cytotoxic gene therapy with 
intensity modulated radiation therapy was studied in a randomized, multisite, 
prospective, controlled phase II/III trial (NCT00583492). The study, completed 
in 2014, revealed that the combination of gene therapy and radiation therapy 
resulted in a 42% relative reduction of biopsy positivity in patients with 
intermediate-risk prostate cancer. In addition, several oncolytic adenoviruses 
delivered promising results in preclinical models and are under evaluation on 
clinical studies 80, 150, 165. The amount of data collected in different clinical trials 
so far, points to an immune-mediated efficacy of oncolytic adenoviruses. 
Therefore, the whole field is now strongly supporting the concept of “oncolytic 
vaccines”, highlighting the importance of innate and adaptive responses 
elicited by the viruses. This aspect is evolving through the work of researchers 
that take into account the evident links between immunology, oncology and 
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